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Executive Summary 
Background: Since 1987, when (M)ACI was first mentioned, the technique 
has been used all over the world to treat osteochondral lesions in the knee. 
Nevertheless, the actual effectiveness of this relatively new treatment option 
is under question: clinical evidence based on controlled trials and long-term 
follow-up is still missing. For these reasons (M)ACI is being reimbursed in 
most countries only under research conditions. 
Methods: systematic literature search in Medline via Ovid, Embase, Coch-
rane Library, NHS-CRD-HTA (INAHTA), ISI WEB of Science, WHO 
Health Evidence Network and Clinicaltrials.gov was complemented by a 
hand search. Inclusion criteria: Controlled clinical studies with more than 
20 patients and a follow-up period of at least one year. 
Results: The effectiveness analysis is based on 9 comparative clinical trials 
and 6 systematic reviews. Within the trials all together 566 patients were 
treated with mosaicplasty vs. ACI, microfracture vs. ACI, and ACI vs. ACI. 
The results show consistency and confirm earlier (international) reviews. 
There is no evidence that ACI or MACI leads to better outcomes in the 
treatment of osteochondral lesions than any of the alternative treatments. 
ACI is not superior; at best equal, at much higher cost. The short term (1-2 
years) and mid-term (5 years) non-inferiority in highly selected active pa-
tients is proven. Long-term data are lacking.  
Conclusion: (M)ACI methods must be considered – though often applied - 
as experimental techniques. The risks of cultivated chondrocyts cannot be 
ignored and should be given more attention.  
 
(M)ACI is – although in 
worldwide use – still 
questioned 
systematic literature 
search complemented 
by hand searching 
9 clinical trials & 6 
systematic reviews met 
the criteria 
equality, non-
superiority in highly 
selected pts. 
experimental 
techniques  
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Zusammenfassung 
Hintergrund: Erstmals 1987 erwähnt, wird (M)ACI als Therapie von osteo-
chondralen Läsionen weltweit eingesetzt. Als junge Therapieform wird die 
klinische Wirksamkeit jedoch aufgrund fehlender kontrollierter klinischer 
Studien und Langzeit Follow-Ups hinterfragt und dementsprechend in nur 
wenigen Ländern – außerhalb von Forschungsprojekten - refundiert. 
Methoden: systematische Literatursuche in Medline via Ovid, Embase, 
Cochrane Library, NHS-CRD-HTA (INAHTA), ISI WEB of Science, WHO 
Health Evidence Network und Clinicaltrials.gov, ergänzt durch eine Hand-
suche. Einschlusskriterien: Kontrollierte Studien mit mehr als 20 PatientIn-
nen und einer Beobachtungszeit von mehr als einem Jahr.  
Ergebnis: Die Wirksamkeitsanalyse basiert auf 9 vergleichenden klinische 
Studien und 6 systematischen Reviews. Die klinischen Studien untersuchten 
insg. 566 PatientInnen in den Gruppen Mosaicplasty vs. ACI, Microfracture 
vs. ACI, und ACI vs. ACI. Die Ergebnisse zeigen große Konsistenz und bes-
tätigen frühere systematische Übersichtsarbeiten. (M)ACI ist anderen – 
etablierten - Intervention gegenüber in der Behandlung osteochondralen Lä-
sionen nicht überlegen. Die Kurzzeit (12 Monate) bis max. mittelfristigen (5 
Jahre) Resultate – an hochselektiven sportiven PatientInnen - waren in allen 
analysierten Gruppen gleichwertig. Gleichzeitig ist (M)ACI deutlich teurer. 
Schlussfolgerung: (M)ACI ist weiterhin als experimentelle Intervention – 
trotz weltweiter Verbreitung – anzusehen. Die Risken kultivierter Chondro-
zyten sind nicht zu unterschätzen. 
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1 Autologous Chondrocyte Implantation/ACI 
1.1 Background & Introduction 
Autologous chondrocyte implantation (ACI), one of the first cell based 
therapies, was first trialled in 1987. Since its introduction into clinical prac-
tice by Brittberg et al. in 1994 [1], more than 15000 patients have been 
treated with different ACI techniques. Patients suffering from osteo-
chondral, or chondral lesions, cannot be adequately treated using established 
treatments. For fifteen years ACI has been believed to lead to better clinical 
outcomes. 
Classical methods are not intended to renew the cartilage itself, but to treat 
the symptoms of a lesion. However, techniques such as drilling and shaving 
can lead to osteoarthritis. Microfracture and bone marrow stimulation result 
in fibrous scar tissue [2], which is different from the normal hyaline carti-
lage found in knee. Mosaicplasty and the osteochondral auto graft transfer 
systems (OATS) require autologous cartilage material and can therefore only 
be used for small lesions. MACI (Matrix associated ACI) – so the expecta-
tion - may be able to overcome this problem and renew the hyaluron carti-
lage tissue. 
Early autologous chondrocyte implantation procedures, used a periosteal 
flap or a collagen sheet to fix the injected cells at the side of lesion [1]. This 
was the major disadvantage of this first generation of ACI. Due to the need 
for this additional coverage and debridement, the surgical procedure was not 
feasible for some cartilages in the knee. To overcome this, new ACI tech-
niques, such as MACI, use a seeded matrix for chondrocytes delivery: This is 
easier to perform, because there is no need for extra coverage. 
As part of the 4th generation of ACI, the use of genetically modified cells, 
which may be of higher quality, is being tested. However, these investiga-
tions have not yet been provided results of clinical relevance. Clinical trials 
are currently analyzing the impact of diverse bioactive matrices and 3D bio-
active matrices on multiple lesion sizes and in different locations. 
Nevertheless, many assessments of (M)ACI have been carried out and only a 
few western countries have decided to reimburse any kind of ACI or to in-
clude the procedure in their health benefit catalogues. This paper, based on 
controlled clinical trials and systematic reviews, aims to compare the out-
comes of established/conventional procedures such as microfracture, drill-
ing, and mosaicplasty, with those techniques that use in vitro cultivated 
cells, such as ACI and MACI. Due to the fact that there are some differences 
between the treatments and procedures, the major goal of this review is to 
synthesize the available evidence on patient-relevant long-term outcomes af-
ter autologous chondrocyte implantation.  
ACI since 1987 
standard therapies: 
microfracture, 
mosaicplasty etc. 
development of ACI:  
3 generations 
future research: 
genetically modified 
cells 
aim of the paper: 
synthesize evidence 
 
Autologous Chondrocyte Implantation 
8 LBI-HTA | 2009 
1.2 Aetiology and Diagnosis 
Traumatic events, as well as several types of arthritis, and spontaneously oc-
curring osteochondritis dissecans (OCD), can lead to cartilage lesions in 
weight bearing knees. In most cases, cartilages are not innervated, and so 
primary processes lead only to inflexibility, swelling and, occasionally, mild 
pain. Therefore the diagnosis is most often confirmed when the diagnosis of 
ligament injury or disease of the meniscus is made, with both indications of-
ten leading to lesions caused by knee instability. Hence, mainly people 
whose knees are put under stress - athletes and people with an abnormally 
high BMI - are affected. 
The development of OCD is normally observed during the second decade of 
a patient’s life, while osteoarthritis develops later on, and is rarely found in 
children and younger adults. Additionally, a self-healing capacity was ob-
served by Messner et al. [3] who reported that previously treated knees be-
came resymptomatic. The patients were symptom-free for 14 years. This 
long symptom-free period can be explained by the ability of tissue to self-
repair. 
There are two hypotheses of cartilage lesion healing. Both have been ob-
served, but both are poorly understood.  
1. The recruitment of non-cartilage-cells (e.g. some blood stem cells): 
their ability to penetrate the lesion is called the extrinsic repair 
pathway, and leads to the softer fibrous cartilage.  
2. The intrinsic repair pathway consists of the proliferation of the 
chondrocytes themselves. In general, due to the restriction of chon-
drocyte proliferation capacity, the intrinsic pathway, is less effective 
in the regeneration of symptomatic lesions.  
Self curing, especially in children and younger adults, has been reported by 
Prakash et al. [4]. 
Two classification systems have been developed and are generally recom-
mended for the evaluation of articular cartilage defects: the Outerbridge 
classification and the ICRS (International Cartilage Repair Society) classifi-
cation. Outerbridge is especially used for patellar defects. The ICRS score – 
more often used today - was unfortunately hardly used in the analysed trials. 
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children not affected: 
self-healing capacity 
cartilage repair: 
2 forms of cartilage 
healing  
 
classification for 
evaluation of articular 
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Table 1.2-1: Outerbridge /ICRS classification [5]: 
Outerbridge Grade 
ICRS 
Grade Description 
  0 No defects 
I 1a Intact surface, fibrillation, and/or softening, swelling 
  1b Additional lesions on surface 
II 2 
Lesion-depth to 50% of cartilage thickness, fragmentation 
and fissuring‹ 0,5 in. in diameter 
III 3a 
>50%, not to calcified layer, fragmentation and fissuring‹ 
0,5 in. in diameter 
 3b >50%, to calcified layer 
 3c >50%, to subchondral plate 
IV 4 exposed subchondral bone (any size) 
 
In the following text, the term “lesion” is defined as Grade 3 or 4. This is 
largely accurate for the patient population analysed in chapter 4. 
Even if age, size, BMI, size of bones and physical activity do not differ, there 
is still a variability of cartilage thickness in the knee of 16-31 % [6] depend-
ing on the gender.  
1.3 Technical Description of ACI & of Alternative  
Treatment Options 
1.3.1 Arthroscopic lavage and debridement 
Debridement is the medical removal of a patient's dead, damaged, or in-
fected tissue to improve the healing potential of the remaining healthy tis-
sue. Lavage (“to wash out”) is carried out with a saline solution and removes 
the inflammatory mediators and any cartilage debris residing in the synovial 
space. This intervention is the first part of all procedures de-scribed in this 
report, and Lavage can be used as a therapy on its own [7]. Additionally of-
ten drilling, shaving or any other kind of mechanical treatment is applied in 
clinical practice. 
1.3.2 Microfracture 
The aim of this technique is to fill lesions with fibrous cartilage. A debride-
ment to the subchondral bone plate, followed by the drilling of multiple 
holes is carried out. Microfracture is one marrow stimulating therapy among 
others, which use cell recruiting channels, such as pridie drilling and abra-
sions-arthroplasty. Microfracture is currently the most frequently used tech-
nique, due to a lower rate of adverse events such as burning of the tissue and 
its high efficiency and low costs compared to other techniques. Microfrac-
ture is largely restricted to lesions smaller than 4 cm in diameter and for pa-
tients with a BMI below 30kg/m². As reported for ACI technique, there is a 
correlation between clinical effectiveness and BMI [8].  
gender-specific 
variability of cartilage 
thickness 
removal of damaged 
tissue via “lavage” 
marrow stimulating 
therapies: 
microfracture, pridie 
drilling, abrasions-
arthroplasty 
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Long-term clinical results show that the cartilage becomes resymptomatic 
after about 5 years, due to the fibrous cartilage [9]. This therapy is often 
compared to ACI. The hospitalisation period is short and the method is per-
formed arthroscopically. This treatment has been reported to lead to hyaline 
cartilage regeneration especially in children and young adults. Isolated cells 
of MFX treated cartilages showed disappointing expression of typ II colla-
gen and osteocalcin, a marker for mineralization and bone formation. 
1.3.3 Mosaicplasty 
In order to regenerate weight bearing cartilage, it can be useful to trans-
plant a non weight bearing part of another cartilage to the site of the lesion. 
Mosaicplasty uses this technique. Mosaicplasty, first trialled in 1993 [10], is 
limited to lesions between 1 and 9 cm². Mosaicplasty has shown to lead to 
the development of hyaline cartilage in a high proportion of patients. This 
type of transplantation technique is also used to treat younger patients. An-
other techniques used in younger patients is osteochondral cylinder trans-
plantation (OCT). 
1.3.4 Total knee replacement 
The knee is replaced by an artificial knee. There are several side effects, in-
cluding swelling, inflammation and pain. Total knee replacement is recom-
mended for older patients only, as the long-term results of the intervention 
are disappointing. However, the development of new materials suggests that 
there could be long lasting prostheses which could be transplanted in 
younger patients without risking the need for further treatment. This 
method is the most cost intensive and is associated with long hospitalisation 
periods. 
1.3.5  (M)ACI 
Common steps 
(M)ACI/ (matrix-induced) Autologous Chondrocyte Implantation is a 
multistep procedure, which varies according to the technique used. All tech-
niques involve the same basic steps [11]: 
Harvesting of cells: The cells are commonly harvested from another healthy 
non-weight-bearing cartilage tissue, while arthroscopy is performed. 
Cultivation of cells: This step is the most flexible part of the therapy, as the 
cells react to millions of different signals. Each signal is processed in a dif-
ferent way, and so each molecule, each temperature shift, and every shift in 
pressure is able to change a cell completely. The quality of a cell-based ther-
apy can be regulated in this step. Usually, the patient’s blood is taken, and 
the serum is isolated, to serve as nutrient medium. The addition of a mixture 
of differentiation factors is controlling the cells quality. Further it is obvious 
that every viral contamination, or contamination by intracellular organisms, 
leads to unexpected and dangerous effects when cells are implanted. 
five years average 
lasting effect 
hyaline cartilage fills 
the lesion 
frequently in elderly 
patients, because of 
unsatisfying long-term 
results 
1. harvesting of cells  
2. cultivation of cells  
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ACI-P and ACI-C 
After debridement the cell suspension is injected in a specially created lid of 
periosteum (ACI-P) or in an artificial collagen lid (ACI-C). This is then 
sealed by fibrin glue and fixed in place.  
In ACI-P, P stands for Periostium, a flap of which covers the sheet. This is  
taken from the proximal tibia, below the pes anserinus [2]. In ACI-C, a col-
lagen layer is used as a cover. ACI is performed using an open surgical pro-
cedure.  
In the last step, the sheet is fixed. It covers the lesion and, depending on the 
protocol, is sealed by the second layer. The sheet is screwed or sutured, de-
pending on position and procedure, to the next healthy cartilage, or to bone.  
MACI  
The cells are loaded upon a collagen layer, and than are positioned arthro-
scopically to the lesion. There it is sealed and sutured. 
Generations of ACI  
Due to technological developments, we are able to distinguish between dif-
ferent generations of ACI [12].  
The 1st generation of ACI refers to ACI-P, the Brittberg method, [1, 13, 14]: 
the cover sheet consists of a Periostium flap.  
The 2nd generation is ACI-C: a collagen is used as a cover.  
The 3rd generation: a bio matrix, seeded in a 3D way (MACI), is used and 
performed arthroscopically. 
The 4th generation (not of clinical relevance today): different genetical meth-
ods, like knockout, knockdown and reprogramming are considered. Fur-
thermore, scaffold free implants are currently being tested on sheep [15]. 
1.3.6 Post-Intervention: Rehabilitation 
Mostly rehabilitation programs are based on different phases of wound heal-
ing. Restrictions on weight-bearing and range of motion are given at the first 
2 weeks. After this non-weight-bearing period, the weight-bearing increases 
slowly, till after 1-2 months the full weight-bearing and full motion range is 
permitted. Physiotherapeutic interventions and non-knee loading sports like 
swimming are recommended. The detailed program is depending on the po-
sition of the lesion. 
1.3.7 Follow-up Methods  
Several methods are used to evaluate the results of the different medical in-
terventions used to treat cartilage lesions: radiology, histology and clinical 
evaluation of the patient´s functional state. Here we are showing the two 
most frequent control assays, MRI as a non invasive method and histology, 
which is requiring a tissue sample. 
3. reproduction & 
multiplication of cells 
on scaffold material 
4. reimplantation, 
fixation 
matrix-based  
technological 
generations of ACI 
aims/ intentions/ 
expectations of 
technological 
generations of ACI 
weight-bearing & range 
of motion  
evaluation of  
state of healing 
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MRI/ Magnetic Resonance Imaging 
MRI allows precise measurement of the thickness and surface of soft tissue. 
MRI is a way of diagnosing early stage cartilage degeneration and preopera-
tively distinguish between articular cartilage, fibrocartilage, and fluid [16], 
and can be used in the long term evaluation of patients´ development [17].  
MRI is one of several follow-up procedures commonly used to measure the 
results of the effects of MACI. The correlation between MRI and histology 
outcomes is reported to be high for ACI-treated patients [18], as much as the 
correlation of clinical outcome and MR imaging in MF and ACI is reported.  
Nevertheless, due to varied and non-standardized protocols, MRI has limita-
tions. 
Histology 
To collect the specimen a control arthroscopy is performed. This is the rea-
son why there is a shortage on healthy samples. This flaw is not given in case 
of an adverse event, which makes a second look arthroscopy necessary. The 
staining of the samples makes the cell pattern visible, according to the used 
stain.  
1.4 Scoring Systems for Evaluation 
Several scoring systems are used to evaluate patients´ functional outcome 
and quality of life/ QoL. 
1.4.1 Tegner-Lysholm Knee score 
The Lysholm Knee scale is a scoring system consisting of eight questions. 
There is a maximum of 100 points, and a minimum of 0 points. The catego-
ries and maximum points are: 
1. Pain; 25 points 
2. Instability; 25 points 
3. Swelling; 10 points 
4. Limp; 5 points 
5. Stair climbing; 10 points 
6. Squatting; 5 points 
7. Use of support; 5 points 
8. Locking; 15 points 
The lack of a sports category reflects the fact that it was originally developed 
to validate the outcomes in older patients. Evaluation is usually completed 
using the Tegner activity scale, with a maximum of 10 points [19]. There is 
evidence that patients and professional physiologists respond differently to 
the Lysholm score, especially in the swelling category [20]. The minimum 
detectable change for the Lysholm scale was 8.9 and 1 for the Tegner activity 
scale. 
problems with direct 
compare  
measures pain & 
functioning  
of knee 
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1.4.2 KOOS/ Knee injury and Osteoarthritis Outcome Score 
The KOOS consists of five categories, with a maximum of 100 points per 
category. They are: 
1. Symptoms 
2. Pain 
3. Activities of daily life 
4. Sports and recreation 
5. Knee related quality of live, QoL 
The scores within the subclasses may be considered alone, or summed to ob-
tain an overall score. It is assumed to be a valid scoring system for ACI [21]. 
KOOS is often reported as an average value of all subclasses. Individual cate-
gory scores are only reported when they are different from the average result.  
1.4.3 SF36, Short Form 36 
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It 
yields an 8-scale profile of functional health and well-being scores as well as 
psychometrically-based physical and mental health summary measures and 
a preference-based health utility index. It is a generic measure, as opposed to 
one that targets a specific age, disease, or treatment group. It uses different 
subclasses to investigate the overall state of the patient [22]. 
1.4.4 VAS, Visual analogue score 
The VAS is used to measure non-discrete parameters such as pain. Pain does 
not appear in discrete categories to patients. The VAS uses a 100 mm “scor-
ing ruler”, where 0 mm represents perfect health [23].  
1.4.5 IKDC scoring 
The IKDC (International Knee Dokumentation Committee) scoring system 
has 7 categories. Answers are given by the patient. 
1. personal data and natural history of disease 
2. acute disease 
3. daily activities, including sports 
4. pain 
5. swelling 
6. sports 
7. function 
100 points represents perfect health and the minimum score is 0. Since 2000 
a second, almost identical, IKDC rating system has been used, but both are 
nearly equal in outcome [24]. 
pain & symptoms,  
but also ADL & QoL 
multi-purpose generic 
instrument for 
measuring total state of 
patient 
measuring pain 
pain & symptoms,  
but also ADL  
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1.5 Patients & Indications 
Autologous chondrocyte implantation is restricted to non-inflamed and non-
genetic diseases of the knee. These restrictions are related to the ability of 
cells to divide and differentiate and therefore are depending on the cells age. 
The patient’s activity and BMI is of importance - fatty tissue is absorbing 
different factors, and hormones, leading to an unresponding system – for the 
selection of the patients. The factor age is discussed controversial. It is re-
ported, that patients over 45 show similar results as younger patients de-
scribed in literature [25]. Aging itself leads to several developments. It is 
necessary to mention that the decrease of range of cellular development op-
tion, the lower hormone response and the lower hormone level are statistical 
facts. Depending on the individual patient, this therapy form is recom-
mended for active patients, and so for patient of younger cellular behaviour, 
but not to younger patients only. 
Lesions of the lateral or medial femoral condyle, of the trochlea, and also 
those of the tibial plateau and patella are said to be treatable using ACI tech-
niques. Mostly, the lesions are the result of traumatic events. However, there 
are also clinical trials on patients with Ahlback syndrome, patients suffering 
from Osteoarthritis dissecans [26] and osteoarthritis patients. Osteochondral 
lesions with 1 cm in diameter, as it is reported to be the limit of self curing 
[9], to 12 cm² may be treated.  
1.6 Regulation and Costs 
(M)ACI has been evaluated over many years in many countries: 
 
Table 1.6-1: ACI-Assessments (see also table 3.4-1) 
Country/ 
Agency 
Year of pub-
lication 
Conclusion of assessment 
France/  
HAS [27] 
2005 As there are insufficient comparative trials with a good level of evi-
dence or long-term follow-up, ACI is an emerging technique still very 
much in the development stage. 
Spain/ 
AVALIA 
[28-30] 
2005, 2008, 
2009 
2005: There is no evidence showing that ACI is better than other pro-
cedures on the treatment of chondral lesions of the knee. With the 
available information, ACI is a safe procedure. 
2008: No evidence that ACI is more effective than other conventional 
techniques in treating chondral lesions of the knee. 
2009: only “guided use” (under conditions such as documentation) 
 
 
 
 
young adults, 
physically active, 
BMI 
  
location & size  
of lesion 
many assessments in 
many countries 
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Country/ 
Agency 
Year of pub-
lication 
Conclusion of assessment 
Great Britain/ 
NCCHTA & 
NICE 
[31, 32] 
2001,  2005 2005: ACI should not be used for routine primary treatment.  All pa-
tients receiving ACI should be enrolled in ongoing or new clinical stud-
ies. 
Scotland/ 
NHS QIS 
[33] 
2005 There is insufficient evidence at present to say that ACI is cost-
effective compared to microfracture or mosaicplasty. 
USA/ BCBS 
USA/ ECRI 
[34, 35] 
2003 
2004 
Not any more available 
Commercial source, assessment not free available 
Sweden/ SBU 
[36] 
2000 No evidence 
Germany/ 
KBV & G-BA 
[37-39] 
2002, 2008, 
2009 
2002: No evidence 
2008, 2009:  Since there is no evidence, no general reimbursement. 
ACI will be re-assessed next time in 2014 
 
Based on several assessment by national HTA-agencies, most countries have 
decided not to reimburse (M)ACI on a general basis, but to leave the inter-
vention in the research context or allow limited “conditional” use. 
Table 1.6-2: Reimbursement in selected countries (INAHTA) 
Norway Research only 
France Research only 
Canada Research only 
Australia Research only 
Israel Research only  
England Research only  
Germany Research only (KBV: next evaluation in 2014) 
Denmark Status “developmental”, only in specific centres  
USA Reimbursed on basis of individual decision 
Italy Reimbursed (to the level of standard knee operation € 3.022.-) 
Spain Reimbursed, since 2009 “guided use” 
Austria Reimbursed  
Belgium Reimbursed 
 
Austria is one of the few countries in which ACI was included in the benefit 
catalogue relatively early. (M)ACI, including explantation, cultivation and 
implantation of cells, has been reimbursed within the Austrian DRG-system 
for many years (tariff about € 6.000.- to 7.000.-). (M)ACI has been carried 
out between 132 (2006) and 193 (2003) times a year, though less frequently 
in recent years. 
most often  
“research only” 
Austria: in the 
reimbursement 
catalogue for  
many years 
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Table 1.6-3: Frequency of (M)ACI in Austria 
MEL 6705 for ACI   
      
  2003 2004 2005 2006 2007 
Burgenland 0 0 0 0 0 
Carinthia 1 0 0 0 0 
Lower Austria 70 26 38 26 25 
Upper Austria 46 57 24 24 33 
Salzburg 5 16 10 14 13 
Styria 22 26 23 30 54 
Tyrol 10 10 13 7 6 
Vorarlberg 4 1 0 4 0 
Vienna 35 69 50 27 12 
Austria 193 205 158 132 143 
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2 Literature Search & Selection 
2.1 Research Question 
1.) Are variable ACI methods a safe and effective alternative compared to es-
tablished (MF, MP etc.) techniques for the treatment of cartilage defects?  
2.) Is there an influence of nouvelle technique/recent generations on effec-
tiveness or safety?  
2.2 Inclusion & Exclusion Criteria 
The criteria for including relevant studies are described in table 2.2-1. 
Table 2.2-1: Including criteria 
Population Patients with grade 3 or 4 cartilage lesions in knee 
Intervention Cell based procedures or products 
Control interven-
tion 
Natural history, placebo, microfracture, mosaicplasty, abrasive techniques, ACI of 
earlier generation, total knee replacement 
Outcomes 
Effectiveness  
 Functioning of knee 
 Pain 
 ADL/ Activities of Daily Living 
 QoL/ Quality of Life 
Safety 
 Revisions/additional treatments 
 Adverse events  
Studies design 
Comparative (randomised and non-randomised) clinical trials (more than 20 pa-
tients)  
Systematic reviews 
 
Publications/ trials were excluded, if 
 they involved fewer than 20 patients  
 they had a follow-up period of less than one year 
 they were non-comparative, only observational 
PICO-Question 
Autologous Chondrocyte Implantation 
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2.3 Literature Search 
The systematic literature search was performed on 01.07.2009. The following 
databases were searched:  
 Medline via Ovid 
 Embase  
 The Cochrane Library  
 NHS-CRD-HTA (INAHTA) 
 ISI Web of Science 
 WHO Health Evidence Network 
 Clninicaltrials.gov 
The search was limited to the period 1987-2009 and to English and German 
publications in Medline. All other databases had no language limits. After 
elimination of the duplicates there were 275 hits. The exact strategy is avail-
able from LBI-HTA. The search strategy was complemented by a manual 
search in scopus.com, ncbi-pubmed, Cochrane, WHO Health Evidence Net-
work, and clinical trials by another investigator. 28 further matches were 
found. 
 
systematic literature 
search in databases & 
networks 
limitation of search 
1987- 2009 
Literature Search & Selection 
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2.4 Literature Selection 
Literature was selected according to the protocol/ PICO presented below. 
Two researchers independently selected the articles. In case of different 
views, consensus was found through discussion. 
After elimination of the duplicates 275 articles were identified in the search 
and 206 were excluded because they covered the incorrect topic. 15 were not 
available as full text and 39 were classified as background literature. 
 
Diagram 2.4-1: Quorum tree  
The studies of Brittberg [1] and Peterson[40] are considered as background 
literature, due to the fact that they are not comparative. However they are 
the largest clinical studies, with a follow-up of up to 10 years.  
 
2 researchers involved 
in selection process 
Full text articles: 
n = 54 
 
Excluded articles: 
n = 206 
Analysed clinical trials and systematic reviews: 
 
n = 15 
 7 randomzied controlled trials 
 2 non randomised controlled trials 
 6 systematic Reviews 
 
Not available full articles: 
n = 15 
Background  
literature  
n = 39 
 
Articles identified by search: 
n = 275 
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3  Results 
3.1 Evaluation of Quality of Studies 
The quality of the studies was evaluated based on transparency in reporting 
(randomization method, base line data, drop-outs, sponsoring) and other 
factors as described in the LBI-HTA methods manual [41]. The quality rat-
ings of the studies (excellent, good, fair, poor) are shown in the extraction 
table. 
Data extraction was done by one reviewer. A second researcher checked the 
correctness of the extraction. Where interpretations of the texts differed, 
consensus was found through discussion. 
3.2 Presentation of Results 
The results of the trials included are presented in tables 4.1-1 to 4.1-3 below: 
4 trials comparing ACI with microfracture, 2 trials comparing various gen-
erations of ACI with each other, and 3 trials comparing ACI with mo-
saicplasty were included. None of the 9 comparative trials were rated as ex-
cellent. 2 were rated as good [42, 43], 6 as fair [7, 44-50] and 1 as poor [51]. 2 
authors Knutsen et al. [44, 45] and Horas et al. [49, 50] published papers on 
the same patients for 2 different follow-up periods.  
The results and conclusions of 6 systematic reviews are presented in 4.5-1. 
The systematic reviews include largely the same trials and therefore only the 
key results are given. 
 
reporting trials: 
randomization method, 
base line data, drop-
outs, sponsoring  
2 researchers involved 
in extraction process 
9 comparative trials:  
7 randomised,  
2 non- randomised  
 
 
6 systematic reviews 
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Table 3.2-1: Comparative studies – ACI vs. microfracture 
Author/Year Knutsen  
2004 [44], 2007 [45] 
Saris 
2008 [42] 
Kon  
2009 [47] 
Visna 
2004 [48] 
Country Norway Belgium, Netherlands, Ger-
many Croatia 
Italy Czech Republic 
Study Design 
N of centres 
RCT, MF vs. ACI 
4 centres 
RCT, MF vs. CCI (non-
inferiority) 
13 centres   
Prospective nonran-
domised CT, MF vs. ACI 
2 centres 
RCT, ACI vs. abra-
sive technique 
(Johnson) 
1 centre 
Sponsor/  
product used 
Norwegian Ministry of 
Health 
Genzyme 
TiGenix NV/ ChondroCelect Hyalograft C Baxter 
Patients 
age/ sex 
N pre-
treatment (sur-
gical interven-
tions) 
Aetiology of de-
fects 
18-45 yr (O/ 33.3:   
31.1), 60% male 
pre-treated: 94 %, (I: 1.6: 
C: 1.4) trauma (65%), osteo-
chondritis dissecans (28%) 
18-50 yrs 
(O/ 33.9: 33.9 ) 
male: 61% : 67% 
pre-treated: 88%: 77%, ≥2 
37%: 21% 
16-60yr  (O/ 29.0: 30.6) 
male: 64.3%: 76.6%:  
pre-treated: 47.5%: 
25%, trauma (56.3%), 
microtraumatic degen-
eration (38.75%), and 
osteochondritis disse-
cans (5%) 
18-50 yr (O/ 29.4: 
32.2) 
male: 72%: 64% 
male 
pre-treated: 89%: 
80% 
trauma (86%) 
osteochondritis 
dissecans (12%) 
Size of lesion 5.1: 4.5 cm2  2.6 ± 1.2: 2.4 ±1.0  cm2 2.2: 2.5 cm2 4.08 (2-10): 3.36 
(2-8.8) cm2 
Indication (in-
clusion)  
2-10cm2 after debridement, 
osteochondral lesions, iso-
lated Outerbridge grade-3 or 
4 defect on medial or lateral 
femoral condyle or trochlea, 
knee is stable, normal stand-
ing radiographs performed 
Symptomatic cartilage lesions 
of the femoral condyle, lesions 
between 1-5 cm2,  
Grade 3 or 4 chondral 
lesions of femoral 
condyle or trochlea 
from 1-5 cm2 
2.0-10.0 cm2 full 
thickness cartilage 
defect, caused by 
trauma, Ahlback 
syndrome, os-
teoarthritis disse-
cans, medial femo-
ral condyle, lateral 
femoral condyle, 
tibial plateau, pa-
tella  
Contra-
indication (ex-
clusion)  
Rheumatoid Osteoarthritis, 
overweight, malalignment 
with 5° valgus or varus com-
pared with normal, patella-
femoral instability, 
Bechterew syndrome, chon-
drocalcinosis, gout 
Advanced osteoarthritis, 
known allergies (penicillin and 
gentamicin, multiple severe al-
lergies), complex ligamentous 
instability of the knee,  Menis-
cal transplant,  Meniscal su-
ture, Meniscal resection, varus 
or valgus malalignment ex-
ceeding 5°, pre-treatment’s: 
mosaicplasty, microfracture 
performed less than 1 year be-
fore baseline, hyaluron acid in-
tra-articular injections into the 
afflicted knee within the last 6 
months, osteoarthritis drugs, 
corticosteroid therapy,  
chronic use of anticoagulants, 
uncontrolled diabetes, osteo-
chondritis dissecans (recent) 
(within 1 year before base-
line); Etc. 
Patella or tibial plateau 
lesion, diffused arthri-
tis, bipolar lesions, knee 
instability, axial devia-
tion, infective, tumor, 
metabolic, inflamma-
tory pathologic changes 
n.r. 
N Patients (I: C) 80 (40:40) 118 (57:61) 85 (43:42) 50 (25:25) 
Pts lost to fol-
low-up, drop 
out  
13 (16%) 59 (50% are missing at 18 
months) 
5 (5.2%) 0 (0%) 
Duration of Fol-
low-up 
2004: 24 months (2004) 
2007: 60 months (2007) 
18 months 60 months 12 months 
Outcome meas-
ures/ scores 
used 
ICRS, VAS, Lysholm, Tegner, 
SF-36 
Overall KOOS (ADL, Pain, 
symptoms/stiffness, QoL) 
IKDC obj. & subj., 
Tegner score,  
Lysholm knee 
score, IKDC subj. , 
Tegner, ICRS 
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Outcome KOOS 
pre/post (I: C) 
n.m. 56.30/74.3:59.53/75.04 n.m. n.m. 
Outcome IKDC 
subjective 
pre/post (I: C) 
n.m. n.m 42 (29-50)/ 84 (63.5-
99.5): 
 40 (30-50) / 70 (60-
80) 
41.28 (11-58) / 
76.48 (45-96): 
45.00 (20-61) / 
68.06 (35-81) 
Outcome IKDC 
objective 
pre/post 
 (I: C) 
n.m. n.m 15% normal & near 
normal / 
90%: 2.5% / 75%  
 
Outcome pain 
pre/post (I: C) 
2004 & 2007:  
54/32/30/28:54/35/28/26 
62.05/79.55:65.47/81.20 n.m.  
Outcome Ly-
sholm function 
pre/post/FU (I: 
C) 
2004 & 2007:  
58/70/72/78: 55/77/75/78 
 
n.m. n.m. 47.60 (19-43) / 
86.48 (57-100): 
52.6 (30-68) / 
74.48 (51-91) 
Good/excellent 
72%: 40% 
Outcome Meyer 
pre/post (I: C) 
n.m n.m n.m. n.m. 
Outcome 
Tegner (prein-
jury) pre/post 
(I: C) 
2004: n.r. 
2007: 3.28/4.05: 3.16/4.36 
n.m. 7/6: 7/5 (7.85), 3.23 /5.92: 
(7.10), 2.30 /4.20 
Outcome Cin-
cinnati pre/post 
(I: C) 
n.m. n.m. n.m. n.m. 
Outcome VAS 
pre/post/FU (I: 
C) 
54/40/35:54/35/32 n.m. n.m. n.m. 
Outcome SF-36 2004 & 2007:  
ACI: no improvement in SF-
36, MF: significant improve-
ment  
n.m. n.m. n.m. 
Diagnostic con-
trols (MRI, his-
tology, arthro-
scopy, histo-
morphometry)  
histology (H&E staining), ar-
throscopy 
more hyaline in ACI 
histology at 12th months 
(H&E, Safarin O, anticollagen 
II AB), histomorphometry (ra-
tio Safarin: collagen), CCI bet-
ter scoring in structural regen-
eration of cartilage tissue/ 
quality of tissue restoration.  
No histology at 3-5 
months: anticolla-
gen 2 AB, no un-
specific staining,  
arthroscopy 
Failure 2004: 2 (5%): 1 (2.5%) 
2007: 9 (23%): 9 (23%) - to-
tal knee replacement 2/5% 
per group, 
1 (1.8%): 2 (3.3%) 1 (2.3%): 1 (2.4%) n.r. 
Side effects/ ad-
verse events 
2004: ACI: reoperation (10 = 
25%) because of tissue hy-
pertrophy,  
psoriatic arthritis (1)  
MF: debridement reopera-
tion (4= 10%), arthrofibrosis 
(1),  
no thrombolytic event, no  
deep infection 
2007: additional shaving or 
trimming  ACI: 10/ 25%, MF 
7/17.5%,   
ACI (1) shaving or trimming 
(4) MF: additional high tibial 
osteotomy (1), additional mi-
crofracture (5), mosaicplasty 
(2),  
AEs 88%: 82% 
Severe AE 12%: 13% 
Frequent: arthralgia (35/57 
CCI, 35/61 MF), joint swelling 
(11/57 CCI, 3/61 MF), joint 
crepitating (7/57 CCI; 1/61 MF), 
hypertrophy (14/25% - - 7 
symptomatic - CCI, 8/ 13% 
MF),  
Severe: deep vein thrombosis 
(1/ CCI), severe tendinitis of 
fascia lata (1/ CCI) 
 
No AE Reactive synovitis 
with exudation in 
ACI group (5/20%) 
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Conclusion by 
authors 
Both methods have accept-
able short term and long 
term results, no significant 
difference in histology of tis-
sue and clinical outcome. MF 
is low cost and minimal-
invasive method and there-
fore preferable. 
CCI has superior structural re-
pair compared to MF, tissue 
was less fibrous and showed 
elements of higher compres-
sive strength. Trial proves 
non-inferiority in short term 
results. Expected clinical bene-
fit may not become manifest 
until at least 2-3 years after 
surgery, because cartilage re-
pair may continue to improve.  
Both treatments have 
shown satisfactory 
clinical outcomes at 
medium-term follow-
up. Authors believe that 
2nd generation ACI is a 
good and potentially 
durable option for the 
treatment of cartilage 
defects. 
The results confirm 
a better outcome 
in pts treated with 
ACI. 2nd generation 
ACI avoids hyper-
trophy or ossifica-
tion 
Comments 
(study quality: 
inter-
nal/external va-
lidity) [41] 
The quality of this paper is 
fair: lack of reporting exact 
baseline data, high dropout 
rate, inadequate follow-up 
procedures and inadequately 
described side effects. 
The quality is excellent: good 
follow-up, good reporting of 
side effects/adverse events, 
drop-out rate is low at 12 
months (0), and 50% at 18 
months. The authors reported 
that not all data had been ana-
lysed at the time of publishing. 
The quality of this 
study is low: no accu-
rate diagnostic follow-
up method and no side 
effects are reported. No 
randomization was car-
ried out, marked differ-
ences in pre-treatment 
rates and traumatic car-
tilage lesions between 
groups. 
The quality of this 
study is fair: lack of 
reporting of exclu-
sion criteria, failure 
rates and only 
short term follow-
up (12 months), 
differences in rates 
of pre-treatment 
and lesion size be-
tween treatment 
groups. 
Rating of study 
quality 
fair good poor fair 
 
Abbreviations 
AB: Antibodies (here monoclonal)  
ACI: Autologous chondrocyte implantation 
ADL: Activities of daily living scale  
AE: Adverse events 
CCI: Characterized chondrocytes implantation  
H&E: Haematoxylin and Eosin staining 
ICRS: International Cartilage Repair Society  
IKDC: International Knee Documentation Committee 
KOOS: Knee injury and osteoarthritis Outcome Score   
MACI: Matrix associated autologous chondrocytes implantation 
MF: Microfracture MP: Mosaicplasty 
MRI: Magnetic resonance imaging  
n.m.: Not measured 
n.r.: Not reported 
OAT: Osteochondral autologous transplantation 
OCT: Osteochondral cylinder transplantation 
RCT: Randomised controlled trial
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Table 3.2-2: Comparative Studies – ACI vs. ACI-C vs. MACI, ACI-C vs. ACI-P 
Author/Year Bartlett 2005 [43] Gooding 2006 [46]  
Country England England 
Study Design 
N of centres 
RCT, MACI  (indication) vs. ACI-C 
1 centre 
RCT, ACI-P vs. ACI-C (indication) 
Sponsor/  
product used 
n.r./academic 
MACI: Tissell, Baxter, ACI-C: Matricel 
Herzogenrath 
n.r./academic 
Patients 
Age/ sex 
Number of pre-treatment (surgical 
interventions) 
Aetiology of defects 
15-50 yr (O/ 33.4: 33.7) 
male: 62%  
pre-treated: O/ 2.1: 2.3  
trauma (43%), chondromalacia patellae 
(18%), osteochondritis dissecans (15%) 
(O/ 30.52: 30.54) 
male: 49%   
pre-treated: O/ 2.09 
trauma (43%), chondromalacia patellae 
(29%), osteochondritis dissecans  (18%) 
Size of lesion 6.1 (1.0-22): 6.0 (1.5-16) cm2 4.54(1-12) cm2 
Indication (inclusion) Osteochondral defects larger than 1 cm2 lo-
cated at medial femoral condyle, lateral 
femoral condyle, patella, trochlea caused by 
trauma, chondromalacia patellae, osteochon-
dritis dissecans, 
Isolated full thickness chondral defect (grade 
4 Outerbridge), located at medial femoral 
condyle, patella, lateral femoral condyle, 
trochlea caused by trauma, chondromalacia 
patellae, osteochondritis dissecans  
Contra-indication (exclusion) Uncorrected joint instability, malalignment, 
bone deficiency  
osteoarthritis, inflammatory joint disease, 
Osteoarthritis, multiple defects, limb mala-
lignment, cruciate instability 
Number of patients (I: C) 91 (47: 44) 68 (33: 35) 
Pts lost to follow-up, 
drop-out 
16 (15%) 0 (0%) 
Duration of follow-up 12 months 24 months 
Outcome measures/ scores used VAS, Stanmore functional rating score, modi-
fied Cincinnati knee score,  
Modified Cincinnati knee score, ICRS  
Outcome KOOS pre/post (I: C) n.m. n.m. 
Outcome IKDC subjective pre/post 
(I: C) 
n.m. n.m. 
Outcome IKDC objective pre/post 
(I: C) 
n.m. n.m. 
Outcome pain pre/post (I: C) n.m. n.m. 
Outcome Lysholm function 
pre/post (I: C) 
n.m. n.m. 
Outcome Meyer pre/post (I: C) n.m. n.m. 
Outcome Tegner pre/post (I: C) n.m. n.m. 
Outcome Cincinnati pre/post (I: C) 44.5/64.1: 41.0/59.0 
Good/excellent outcome: 72.3%: 59.1%  
45/62: 45/67 
 Good/excellent outcome: 66.4%: 74.3% 
Outcome VAS pre/post (I: C) 6.0/4.1: 6.0/4.3 n.m. 
Diagnostic controls (MRI, histol-
ogy, arthroscopy) 
Arthroscopy, histology (H&E staining, Safarin 
O), 
Arthroscopy, histology (Safarin O staining 
only),  
Failure 2 MACI (4.3%): 0 (0%) ACI 2 ACI-P (6%)  
Side effects/ adverse events hypertrophy (3 MACI, 4 ACI), manipulation 
of knee under anaesthesia (3 MACI, 3 ACI), 
superficial would infection (1 MACI) 
3 (4%) major and 36 (53%) minor complica-
tions, ACI-C: Deep vein thrombosis (1), Me-
niscal tear shaving (3), lateral popliteal nerve 
neuropraxia (1), superficial wound infection 
(1), large plica removed (1), division of adhe-
sion and graft hypertrophy (1), septic arthritis 
(1),  
Both: Hypertrophy (12/33-ACI-P, 1/35 ACI:C), 
reflex sympathetic dystrophy (1/1),  
Conclusion by authors Both ACI-C and MACI resulted in significant 
improvements within one year: functional 
and pain scores not significantly different, no 
difference in histological findings after both. 
Both interventions are associated with fewer 
graft-related complications and re-operations 
(compared to ACI-P). Little is known of the 
long term durability of MACI. 
This study suggests that the results are com-
parable based on clinical outcome and arthro-
scopic assessment at 2 years. However, the 
most striking feature was the high incidence 
of graft hypertrophy in the ACI-P group caus-
ing considerable morbidity and additional 
surgery. 
Comments (study quality: inter-
nal/external validity) [41] 
The quality of the study is good: reporting of 
all relevant data and high quality of histo-
logical and functional follow-up. 
The quality of the study is fair: in some pas-
sages text/tables are nor congruent. The 
complications are reported in detail. 
Rating of study quality good fair 
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Table 3.2-3: Comparative studies – ACI vs. mosaicplasty 
Author/Year Bentley 2003 [51] Dozin 2005 [7] Horas 2000 [49], 2003 [50] 
Country England Italy Germany 
Study design 
Number of centres 
RCT, ACI-C vs. MP 
1 centre 
RCT, ACI-P vs. MP 
multicenter  
non randomised CT, ACI-P vs. 
OCT 
1 centre 
Sponsor/  
product used 
Commercial 
n.r. 
Italian Ministry of Health 
n.r. 
academic 
Cylinder: DBCS, Merck 
Patients 
age/ sex 
Number pre-treatment 
(surgical interventions) 
Aetiology of defects 
16-49 yr (O/ 30.9:31.6)
male: 57% 
pre-treated: 1.5 (0-4)  
trauma (46%), osteochondri-
tis dissecans (19%), chondro-
malacia patellae (14%) 
16-40 yr (O/ 29.6: 27.9) 1 
male: 77.3%: 45.5  
pre-treated: none 
18-45yr (O/ 31.4: 35.4) 
male: 40%: 75%  
pre-treated: 20%: 15% - 1 
trauma (100%) 
Size of lesion 4.66 (1-12.2) cm2 1.97±0.43: 1.88±0.45 cm2 4.4 (3.2-5.8) cm2 
Indication (inclusion) n.r. Symptomatic chondral injury of 3-
4° (Outerbridge), caused by 
traumatic, microtraumatic influ-
ence, pain, swelling, pseudolock-
ing, femoral condyle, patella, le-
sions size: up to 2.84 cm2   
Trauma caused only, medial 
femur condyle, lateral femur 
condyle  
Contra-indication (exclu-
sion) 
n.r. Subchondral bone injury, no pre-
vious surgical treatment of inter-
est, overweight, knee joint insta-
bility, associated meniscus dam-
age, injured anterior cruciate 
ligaments, axial misalignment, 
rheumatoid joint disease, previous 
or current neoplasty, HIV, HBV, 
HCV viral infection    
Knee joint instability, kissing 
lesions, axial malalignment, os-
teochondral tumor  
 
Number of patients (I: C) 100 (58:42) 44 (22:22) 40 (20:20) 
Pts lost to follow-up, 
drop-out 
n.r. 21 (30 % spontaneously cured be-
fore treatment, 17 % refused sur-
gery) 
0 (0%) 
Duration of follow-up 19 months (12-26) 36 months 24 months 
Outcome measures/ scores 
used 
ICRS, Cincinnati score, Stan-
more score 
IKDC, Lysholm Knee scaling core Modified Lysholm, Meyers, 
Tegner,  
Outcome KOOS pre/post 
(I: C) 
n.m. n.m. n.m. 
Outcome IKDC subjective 
pre/post (I: C) 
n.m. n.m. n.m. 
Outcome IKDC objective 
pre/post (I: C) 
n.m. n.r. n.m. 
Outcome pain pre/post (I: 
C) 
n.m. n.m. n.m. 
Outcome Lysholm func-
tion pre/post (I: C) 
n.m. 90-100: 45%: 68%  
60-90: 22.7%: 9.1% 
25-65: 28-72 
Outcome Meyer pre/post 
(I: C) 
n.m. n.m. 9-16: 9-16 
Outcome Tegner pre/post 
(I: C) 
n.m. n.m. 2-5: 2-5 
Outcome Cincinnati 
pre/post (I: C) 
88% excellent or good: 69% n.m. n.m. 
Outcome VAS pre/post (I: 
C) 
n.m. n.m. n.m. 
Diagnostic controls (MRI, 
histology, arthroscopy)  
Arthroscopy Arthroscopy, radiology MRT, arthroscopy, histology 
(H&E, Mason Goldner, Tolu-
idin-Blau, Immunological: An-
ticollagen  1, 2, 3, 6, 10, Aggre-
can, S-100 protein, monoclonal 
ABs), electron-microscope,  
Failure n.r. n.r. 1 (ACI) 
Side effects/ adverse 
events 
1 vein thrombosis (1), 
infection (1) 
n.r. OCT: oedema (1),  
ACI: hypertrophy (2), mainly 
fibrous cartilage,  
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Conclusion by authors The study has shown, that 
both MP and ACI give encour-
aging clinical results after a 
mean period of 1 year, but MP 
appears to deteriorate with 
time. Definite evidence that 
ACI is valuable for selected pa-
tients, the continued use of 
MP appears to be dubious. 
ACI and MP are clinically equiva-
lent and similar in performance. 
The high percentage of spontane-
ous improvement (1/3 of the pa-
tients) observed after simple de-
bridement calls into question the 
need for prompt surgical treat-
ment of patients with lesions in-
cluded in the study. 
Both treatments resulted in 
decrease of symptoms. Im-
provement provided by ACI 
(85% of pts.) lagged behind 
that provided by OCT (85%). 
Histology shows that the de-
fects treated with ACI were 
primarily filled with fibrocarti-
lage, whereas OCT retained 
their hyaline character. 
Comments (study quality: 
internal/external validity) 
(LBI_manual)[41] 
Although this is one of the 
most citied studies, the quality 
of the study is poor: lack of 
reporting of baseline data that 
allow comparison of groups, 
esp. lesion sizes, no inclu-
sion/exclusion criteria, no 
dropout or lost to follow-up 
rates, side/adverse effects are 
inadequately described. The 
randomization process is not 
described. 
The quality of this study is fair: 
the reasons for the high drop-out 
rate are reported transparently. 
No side effects/adverse events or 
failure rates are reported, one ad-
ditional outcome (IKDC) was 
measured, but not reported, his-
tology as diagnostic control is 
missing. The study seems to have 
a high external validity and can 
best be described as “environ-
mental” study. The lesions are 
small compared to the other stud-
ies. 
The same trial has been pub-
lished twice: in German (2000) 
and in English (2003). The 
quality of this study is fair: not 
randomised, has a broad range 
of physiological follow-up 
methods, the functional as-
sessment is reported inade-
quately in 2000 though more 
precisely in 2003. 
Rating of study quality poor fair fair 
 
3.3 Effectiveness 
3.3.1 ACI vs. MF 
All of the 4 comparative trials on ACI vs. microfracture were (fully or partly) 
commercially sponsored. Overall the 4 trials included 424 patients between 
the ages of 16 and 60, of whom about two thirds were male. 80-95% were pre-
treated, (fewer in [47]), including patients with symptomatic cartilage le-
sions with lesion between Ø 2.2 to 5.1 cm² and Outerbridge grades 3-4. The 
lesions were most often caused by trauma or osteochondritis dissecans. 3 of 
the 4 trials with follow-up periods of 1 to 5 years concluded that the 2 inter-
ventions led to equal or similar clinical outcomes, but that the cost of mi-
crofracture was much lower. Only 1 study (quality rating fair because 0f lack 
of important of information). [48] reported better results for the ACI treated 
group compared to controls.  
Knutsen et al. [44, 45] performed their trial on medium sized lesions, mainly 
in male patients, in the medial or lateral femoral condyle or trochlea. The 40 
patients in each group, ACI-P and MF, showed a similar pre-treatment rate 
of nearly 1. procedures. The age was higher in the ACI group than in the MF 
group (33. compared with 31.) and the defect size was larger in ACI group 
(5. compared with 4. cm²). Not all of the defects were Outerbridge grade 3 or 
4. 3 were a grade 2 defect, which were rated by other authors as normal carti-
lage. The group in which these were observed was not reported. 
Even though the trial showed superior ACI results after two years [44, 45], 
three years later [44, 45] the results were approximately equal: all scoring 
parameters were significantly raised with both interventions. Histological 
parameters showed that ACI can lead to the development of hyaline carti-
lage. It appears that the cartilage can have mixed properties: Fibrous as well 
as hyaline like tissue was found in the ACI-group. 
4 comparative trials: 
2 thirds male,  
mostly pre-treated, 
grade 3-4 lesions 
Knutsen et al. 2004, 
2007 
80 pts 
2 & 5 years follow-up 
only short term 
superiority of ACI,  
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The diagram shows outcomes after 2 and 5 years. After 2 years, the failure 
rate was low in both groups: 2 in the ACI and 1 in the MF group. The mean 
time to failure was 26 months. There were 9 failures in both groups. All fail-
ures had to be retreated using a surgical procedure. In each group one pa-
tient was retreated by total knee replacement, and the others had MF, MP or 
ACI. Younger and more active patients had significantly better outcomes in 
both treatment groups. The authors concluded that there is a need for im-
provement in surgical and molecular biological techniques, as well as a need 
for further long term studies. 
 
Figure 3.3-1: Knutsen [44, 45] 
Saris et al. [42] carried out a trial in 118 patients and had very specific inclu-
sion criteria. Only patients with lesions on the femoral condyle and limited 
to small to medium sized full thickness lesions were included. The baseline 
data of the groups were similar in terms of pre-treatment, age, BMI, the 
body weight and the height. Only the number of pre-treatments differed be-
tween the two groups. Unfortunately only data from 59 (50%) of the 118 en-
rolled patients were available/ presented after the follow-up period of 18 
months. Both interventions showed a very low failure rate: 1 for ACI and 2 
for MF. The ACI procedure was performed according to the method de-
scribed by Brittberg and was similar to ACI-P. 
Although Safarin O and Collagen 2 staining showed ACI to lead to better 
structural regeneration of the cartilage tissue - the KOOS subgroup scores 
increased by 20% after 18 months - there were no differences between MF 
and ACI. QoL scores increased by about 15% for ACI and by about 21% for 
MF. These results suggest a superiority of structural repair in ACI charac-
terized by a higher grade of hyaline cartilage areas. This superiority is not 
confirmed by the functional assessment of the 2 patient groups: the out-
comes are equal after 18 months. 
 
younger & more active 
patients had 
significantly better 
outcomes in both 
treatment groups 
 
no difference between 
interventions after 5 
years 
Saris et al. 2008 
118 pts. 
limitation of study-
results: 50% of pts lost 
to follow-up 
superiority of ACI in 
structural repair,  
but superiority of  MF 
in QoL  
 
equality in functionality 
after 18 m 
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Figure 3.3-2: Saris [42] 
In a non-randomised clinical trial 80 active patients with grade 3 or 4 
chondral lesions of the femoral condyle or trochlea of 1-5 cm² were treated 
by Kon et al. [48] using ACI (42) or MF (38). Mean ages were 29 in the MF 
and 30.6in the ACI group. The number of males was higher in the ACI-
group. The cause of the lesion was significantly different between the 
groups. In the MF group the main cause was traumatic events, and in the 
ACI group the main causes were traumatic events and microtraumatic de-
generation. There were more pre-reated patients in the ACI-group than in 
the ACI group. The mean lesion sizes were relatively small: 2. (MF) and 2. 
(ACI) cm². The study population had a high average pre-lesion level of 
physical activity and the average time to return to sports activities was short. 
 
Figure 3.3-3: Kon [47] 
Two and five year results were evaluated. At baseline 2.5% of knees in the 
MF group (IKDC scale) were nearly normal. After 5 years 75% were normal. 
In the ACI group 15% of knees at baseline were normal. After 5 years follow-
up this figure was 90%.The Tegner score (measures the functioning of the 
knee) also improved, and the sports activity level was maintained. The trial 
showed that at 5 years follow-up, there was no difference between the out-
comes of  the two interventions. Based on the results of the IKDC score, bet-
ter results were observed in the ACI group, but not so according to Tegner. 
Only 1 failure in each group was reported. The authors conclude that this 
kind of ACI (Hyalocraft C) is an acceptable treatment option. However, nei-
ther an MRI nor a histological analysis has been carried out. 
 
Kon et al. 2009 
80 pts. 
“only” 48% pre-treated 
small lesions 
highly active pts. 
 
 
 
 
2 & 5 years follow-up: 
no difference between 
interventions, 
equality 
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Visna et al. [48] carried out an RCT comparing ACI with abrasive technique 
in 50 patients. The average lesion size in the ACI group was 4.08 cm², in the 
control group it was 3.36 cm². All patients had full thickness cartilage de-
fects, mostly caused by trauma. ACI shows superiority in all parameters (Ly-
sholm, IKDC, Tegner). The authors conclude that 2nd generation ACI leads 
to better outcomes than abrasive techniques after one year. 
 
Figure 3.3-4: Visna [48] 
 
3.3.2 ACI vs ACI Methods 
Two RCTs [43, 46] with a total of 159 patients focused on the evaluation of 
the impact of new (ACI) methods on the clinical effectiveness of ACI. The 
sponsors of both studies are not reported and are believed to be academic. 
The quality of these trials was rated as fair [46] and good [43] respectively. 
The follow-up periods were 12 months [43] and 24 months [46].  
Figure 3.3-5: Bartlett [43] 
The study comparing  ACI with MACI, performed by Bartlett et al in 2005 
[43] is the only controlled clinical trial directly comparing these 2 genera-
Visna et al. 2004 
50 pts. 
only 12 m follow-up 
superiority of ACI in all 
parameters 
2 RCTs  
Bartlett et al 2005  
91 pts. 
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tions of ACI. The results suggest similar outcomes for MACI and ACI-C af-
ter one year. 107 patients were pooled, and 91 of them were later random-
ised. The baseline data of the 2 groups were clearly different.  The lesions of 
the patients in the ACI group had been pre-treated more often than those of 
the MACI group. The mean baseline Cincinnati score was 44.5 for MACI 
and 41.0 for ACI. The mean lesion size was almost the same in both groups, 
6.0 and 6.1 cm². 
After one year follow-up the ACI-C group had an increase of 18 points to 59 
and the MACI an increase of 20 points to 64.1 in the Cincinnati ranking. 
The Stanmore score (not shown) showed almost identical improvements in 
both groups. The VAS score decreased by 2 points in both groups. None of 
the scoring systems showed significant differences between the two groups. 
Histological analysis - not performed on every patient - showed that there is 
only in 42.9% other filling than pure fibrocartilage in the ACI group, and in 
36.4% in the MACI group. 
The similarities in results might suggest that MACI is preferable to ACI, ow-
ing to its more straightforward surgical protocol. However, the study showed 
that the clinical results were not as good when patients had been pre-treated, 
and there were a higher percentage of patients with a failed previous therapy 
in the ACI-C group. Because they compared imbalanced groups, the authors 
recommend considering MACI as an experimental treatment, and underline 
the need for further long term trials. 
Gooding et al. [46] compared first generation ACI (ACI-P) with second gen-
eration ACI (ACI-C). In total 68 patients were randomised into the two 
groups.  
Besides the (equal) mean age of the patients, no other baseline data are re-
ported. The ACI-P group showed - after two years follow-up – an increase in 
the Cincinnati score from 39.4% good, 33.3% fair and 27.3% poor (baseline), 
to 30.3% excellent, 36.4% good 21.2% fair and 12.1% poor. The baseline 
scores in the ACI-C group were with 5% lesser “good”, 10% higher “fair” 
and 4% “lower” poor Cincinnati scores. 
Overall, the results are very similar for the two interventions. A one and two 
year follow-up arthroscopy showed that ACI-C resulted in Outerbridge 
grades 1 or 2 for 79% of patients one year after and 82% two years after sur-
gery. This is an improvement, but these partly fillings had been reported in 
both groups as being soft. 80.7% of ACI-P patients had Outerbridge 1 or 2 
lesions after one year, and, in a smaller population, only 55% after two years. 
Histological analyses were carried out in a small group of ACI-C patients af-
ter one year: the results showed that mixed cartilage or fibrous cartilage, but 
not hyaline alone developed. After two years this outcome had changed only 
little: out of 7 patients only one had been reported to have developed hyaline 
cartilage. Results in the ACI-P group were similar. After 1 year, only 1 of 8 
patients was developing hyaline cartilage, after two years this was the case 
for 2 of 14 patients. The arthroscopic results showed that there was not a 
complete healing of the lesion. Gooding et al [46] conclude that the Perio-
stium patch is not necessarily needed for ACI.  
 
MACI and ACI:  
clinical unimportant 
differences,  
equal results 
preference of MACI due 
to easier surgical 
protocol  
Gooding et al. in 2008  
68 pts. 
nearly equal results, 
decrease in Outerbridge 
grading from 3-4 to 1-2 
 
same cartilage 
consistence 
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3.3.3 ACI vs Mosaicplasty (MP) 
Trials comparing ACI to mosaicplasty and related techniques were per-
formed on 184 patients by Horas el al. 2000 [49] and 2003 [50], Bentley et al. 
2003 [51] and Dozin et al. 2005 [7]. The results differ greatly. The Horas et 
al. [49, 50] and Dozin et al. [7] trials compared ACI-P methods to MP, while 
Bentley et al. [51] compared ACI-C to MP. One trial [51] was commercially 
funded, the two others by academic or public funds. 
The Bentley et al. [51] study enrolled 100 patients and was commercially 
funded. It was rated as “poor”, due to lack of reporting of baseline data, in-
clusion/exclusion criteria, and details of adverse effects. Furthermore, they 
used an accelerated – uncomparable - rehabilitation protocol. The authors 
conclude that MP can be replaced by ACI-C in selected patients, but ade-
quate evidence for this conclusion is not provided in the publication. 
The Dozin et al. [7] study shows a very high drop-out rate, caused by spon-
taneous healing. After debridement had been performed 6 months prior to 
surgery, 30% of the patients had healed spontaneously by the time they were 
due to have their procedures. 
Figure 3.3-6: Horas [49, 50] 
The Horas et al. [49, 50] study enrolled 40 patients who were equally dis-
tributed between the ACI-P and the OCT group. The baseline characteristics 
of the patients were somewhat different in terms of average age (31.4 years in 
the ACI group vs. 35.4 years in the OCT group), but pre-treatment rates and 
localisation of the lesions were the same. The size of the lesions was not re-
ported and the 2 years results were presented. The reported scores (Lysholm, 
Meyer, Tegner) showed very similar and significant improvements after 2 
years in both groups. The results tended to favour the OCT intervention. 
The MRT showed a statistically significant decrease of the signal in the OCT 
group after 2 years. The ACI group showed differences between the signal of 
the natural cartilage tissue and the reclaimed material after two years. Ar-
throscopy of the ACI group proved that regeneration was not taking place. 
The tissue showed a different elasticity than the normal tissue and had a 
rough surface. The OCT group showed nearly perfect regeneration. Immun-
histochemical analysis showed similar results in both groups. OCT was well 
integrated, while the ACI reclaimed material was distinguishable from the 
surrounding tissue. Electron microscopic analysis showed a high migrating 
2 RCTs,  
1 non-randomised CT 
Bentley et al 2003 
100 pts 
poor reporting of trial 
low evidence in favour 
of ACI 
Dozin et al. 2005 
44 pts 
30% spontaneous 
healing prior to surgery 
Horas et al. 2000, 2003 
40 pts. 
 
significant 
improvements in both 
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tendency or high cell death rates of the reimplanted chondrocytes in the ACI 
group, caused by holes of a diameter of one chondrocyte. The collagen struc-
ture was of normal appearance in the OCT group, collagen fibers of the ACI 
group had another 3D structure. 
3.4 Results in Systematic Reviews 
Systematic reviews were written by Clar et al. [5], Jobanputra et al. [31] 
Magnussen et al. [52], Ruana-Ravina et al. [28], Vavken et al. [53] and 
Wasiak et al. [54]. All of them analysed more or less the same clinical trials 
as described above. Some included/ differences are:  
 trial designs other than RCTs, including observational studies 
and/or 
 analysis/ assessment of evidence on effectiveness alone or com-
plemented by economic assessment  
Table 3.4-1: Conclusions from systematic reviews  
pts  
randomised 
pts 
not randomised 
Jobanputra 2001 
[31] 
0 2600 
Conclusion 
Economics:: unclear 
Long term outcomes are required 
pts  
randomised 
pts  
not randomised/ 
observational Clar 2005  
[5] 
266 101 
Conclusion 
There is insufficient evidence at present to say that 
ACI is cost-effective, long term outcomes are re-
quired. 
pts  
randomised 
pts  
observed 
Magnussen 2008  
[52] 
421 0 
Conclusion 
No one technique produces superior clinical results 
for treatment of full-thickness articular cartilage de-
fects.  
Available evidence shows limitations 
pts 
randomised 
pts 
 not randomised Ruano-Ravina 
2005 
[28] 
220 464 
Conclusion 
The clinical trials yielded no evidence that ACI was 
superior to the therapeutic alternatives.  
Neither in safety nor in effectiveness is a difference.
pts  
randomised 
pts 
not randomised Wasiak 2006  [54] 
266 0 
Conclusion 
Long term outcomes are required 
pts 
randomised 
pts 
not randomised 
Vavken 2008 
[53] 
 
276 220 
Conclusion 
ACI leads to high quality repair, and therefore 
should be preferred because of economic superiority
 
6 systematic reviews 
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Jobanputra et al. 2001 [37] included 17 studies in their review. At least 2600 
patients appear to have been treated with autologous chondrocyte transplan-
tation (ACT). All included studies were case series with a variable length of 
follow-up. With one exception, all the studies reported improvements in pa-
tient status, usually over a follow-up period of less than 2 years. The out-
come of ACT surgery was rated as ‘good’ or ‘excellent’ by approximately 
70% of patients 2 years after treatment. Approximately 16% of patients re-
quired further arthroscopic surgical procedures during follow-up, and 
treatment was judged to have failed in 3–7% of patients. For comparator 
treatments, the outcome was rated as ‘good’ or ‘excellent’ in 10–95% of pa-
tients 2 years after treatment. 
For cost-calculations two economic studies, one carried in the USA and the 
other in Sweden, were included. Neither study compared ACT with other 
treatments. Using data from these studies and other sources, it was esti-
mated that ACT performed in the UK would cost £4667 or £8167 for cell cul-
ture and surgery, depending on which service provider was used for cell cul-
ture. Incremental cost over 2 years, when set against comparator treatments, 
was estimated to be £3771 or £7271 (base case) for cell culture, surgery and 
rehabilitation.  
The authors conclude, that the reported literature on ACT and comparators 
is subject to bias because of the inherent weaknesses of case series. In addi-
tion, the long-term impact of conventional surgical treatments or no surgical 
treatment is poorly documented. The cost-effectiveness analysis is similarly 
limited by the poverty of the effectiveness data on both. 
Clar et al. 2005 [5] published a review providing guidance (issued by the Na-
tional Institute for Health and Clinical Excellence/(NICE) in December 
2000. 4 randomised controlled trials were included, as well as observational 
data from case series. The trials studied a total of 266 patients and the obser-
vational studies up to 101 patients. Two studies compared ACI with mo-
saicplasty, the third compared ACI with microfracture, and the fourth com-
pared MACI with microfracture. Follow-up was 1 year in 1 study, and up to 
3 years in the remaining 3 studies. The first trial of ACI versus mosaicplasty 
found that ACI gave better results than mosaicplasty at 1 year. Overall, 88% 
had excellent or good results with ACI versus 69% with mosaicplasty. About 
half of the biopsies after ACI showed hyaline cartilage. The second trial of 
ACI versus mosaicplasty found little difference in clinical outcomes at 2 
years. Disappointingly, biopsies from the ACI group showed fibrocartilage 
rather than hyaline cartilage. The trial of ACI versus microfracture also 
found only small differences in outcomes at 2 years. Finally, the trial of 
MACI versus microfracture contained insufficient long-term results, but 
showed the feasibility of doing ACI by the MACI technique. The authors 
conclude that the existing data suggest that after ACI, it takes 2 years for 
full-thickness cartilage to be produced. 
Reliable costs per quality-adjusted life-year (QALY) could not be calculated 
owing to the absence of necessary data. Simple short-term modelling sug-
gests that the quality of life gain from ACI versus microfracture would have 
to be between 70 and 100% greater over 2 years for it to be more cost-
effective within the 20,000-30,000 £ per QALY cost-effectiveness thresholds. 
However, if the quality of life gains could be maintained for a decade, in-
crements relative to microfracture would only have to be 10-20% greater to 
justify additional treatment costs within the cost-effectiveness band indi-
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cated above. Follow-up from the trials so far has only been up to 2 years, 
with longer term outcomes being uncertain. 
The authors conclude, that there is insufficient evidence at present to say 
that ACI is cost-effective compared with microfracture or mosaicplasty. 
Long-term outcomes are required. Economic modelling using some assump-
tions about long-term outcomes that seem reasonable suggests that ACI 
would be cost-effective because it is more likely to produce hyaline cartilage, 
which is more likely to be durable and to prevent osteoarthritis in the longer 
term (e.g. 20 years). Further research is needed into earlier methods of pre-
dicting long-term results. Basic science research is also needed into factors 
that influence stem cells to become chondrocytes and to produce high-
quality cartilage, as it may be possible to have more patients developing hya-
line cartilage after microfracture. Study is also needed into cost-effective 
methods of rehabilitation and the effect of early mobilisation on cartilage 
growth. 
Magnussen et al. 2008 [52] asked whether ACI or osteochondral autograft 
transfer yields better clinical outcomes compared with one another or with 
traditional abrasive techniques for treatment of isolated articular cartilage 
defects and whether lesion size influences this clinical outcome. They identi-
fied 5 randomised, controlled trials and 1 prospective comparative trial 
evaluating these treatment techniques in 421 patients. The operative proce-
dures included ACI, osteochondral autograft transfer, MACI, and microfrac-
ture. Minimum follow-up was 1 year (mean, 1.7 years; range, 1-3 years). All 
studies documented greater than 95% follow-up for clinical outcome meas-
ures. No technique consistently had superior results compared with the oth-
ers. Outcomes for microfracture tended to be worse in larger lesions. All 
studies reported improvement in clinical outcome measures in all treatment 
groups when compared with preoperative assessment; however, no control 
(non-operative) groups were used in any of the studies. A large prospective 
trial investigating these techniques with the addition of a control group 
would be the best way to definitively address the clinical questions.  
Ruano-Ravina et al. 2005 [28] examined 3 clinical trials and 9 case series. 
The clinical trials yielded no evidence that ACI was superior to the thera-
peutic alternatives with which it was compared. In contrast, the case series 
revealed an improvement in patients. However, as with the clinical trials, the 
follow-up periods were usually very short. In general few adverse events were 
observed, indicating that ACI is a safe technique. The authors conclude, that 
available data afford no evidence that ACI is more effective than other con-
ventional techniques in treating chondral lesions of the knee. 
Wasiak et al. [54] is a Cochrane Review from 2006: 4 randomised controlled 
trials (266 participants) were included. One trial of ACI versus mosaicplasty 
reported statistically significant results for ACI at one year, but only in a 
post-hoc subgroup analysis of participants with medial condylar defects; 
88% had excellent or good results after ACI compared with 69% after mo-
saicplasty. A second trial of ACI compared with mosaicplasty found no sta-
tistically significant difference in clinical outcomes at two years. There was 
no statistically significant difference in outcomes at two years in a trial com-
paring ACI with microfracture. In addition, 1 trial of matrix-guided ACI 
compared with microfracture did not contain enough long-term results to 
reach definitive conclusions. The authors conclude that the use of ACI and 
other chondral resurfacing techniques is becoming increasingly widespread, 
but that there is at present no evidence of significant difference between ACI 
long-term outcomes are 
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Magnussen et al. 2008 
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and other interventions. Additional good quality randomised controlled tri-
als with long-term functional out-comes are required. 
Vavken et al. 2008 [53] reviewed 6 randomised controlled studies on the ef-
fectiveness of ACT compared with microfrature or mosaicplasty. 4 studies 
report no or only insignificant differences - one of them recently presented 
5-year results - whereas 2 studies observed better results with ACT. Long-
term results are good throughout, but the high quality of the regenerative 
tissue is a clear advantage of ACT. Cost-effectiveness models support ACT 
for the longevity of its results and thus relatively lower costs in the long-
term. The authors conclude, that ACT is an expensive and complex proce-
dure and that in direct comparison with alternative treatments ACT pro-
duces results at least as good in the short-term, and most likely better in the 
long-term due to the high quality repair tissue. Thus higher initial costs are 
compensated for with time, so the expectations. 
To summarize, the systematic reviews include, to a large extent, the same 
trials as have been described in this review. Most of them state the short-
term equality (for a much higher prize) and the need for further long term 
trials. 
3.5 Safety & Morbidity 
Table 3.5-1 Safety and Morbidity  
Revisions: additional surgical 
procedures  
Repetition of primary intervention 
Trimming 
High tibial osteotomy 
Debridment 
Adverse events Psoriatic arthritis 
Graft hypertrophy 
Arthrofibrosis 
Deep vein thrombosis 
Severe tendinitis of fascia lata 
Arthralgia 
Joint swelling 
Joint crepitation 
Reactive synovitis with exudation 
Superficial would infection 
Meniscal tear overgrowth 
Lateral popliteal nerve neuropraxia 
Large plica removed 
Septic arthritis 
Reflex sympathetic dystrophy 
Edema 
 
 
Vavken et al. 2008  
short-term equality 
possibility of better 
long term results  
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The most frequently reported side effects for microfracture, mosaicplasty, 
ACI and MACI are joint swelling, joint crepitation, arthralgia and graft hy-
pertrophy. Additionally the need of surgical revision is reported commonly 
for ACI, MACI and microfracture. 
Due to inconsistent reporting aggregated statements are barely possible and 
may likely be biased. However, from the included studies there can be sum-
marised a tendency for ACI and MACI to lead to the highest rates of surgical 
revisions. Joint swelling and arthralgia is common in microfracture and ACI. 
Highest rates of graft hypertrophy and crepitation are found in ACI. Rare 
side effects include deep vein thrombosis, edema, superficial wound infec-
tion, reactive synovitis as well as psoriatic arthritis, arthrofibrosis, tendinitis, 
meniscal tear overgrowth, nerve neuropraxia, septic arthritis and reflex 
sympathetic dystrophy 
 
surgical revision and 
side effects  
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4 Discussion 
In this review only comparative clinical trials (7 randomised, 2 non-
randomised) involving 566 patients were included. All of them were carried 
out by different trial groups, which used different products and procedures. 
Nevertheless the clinical results are consistent in their suggestion that ACI 
and (M)ACI lead to similar short term (1-2 years follow-up) and medium 
term (2-5 years follow-up) results compared to microfracture and mo-
saicplasty. These findings support the results of the 6 systematic reviews 
(Cochrane Report, HTA-reports) written 2001 to 2008. 
Only a few trials suggested that ACI patient outcomes were better than con-
trol group outcomes. However, in all these studies, baseline data varied sig-
nificantly between the groups. The results of trials with positive outcomes 
comparing ACI techniques to conventional techniques were not sufficient to 
lead to statistical significant differences. The majority of trials are ignoring 
the MRI method. Differences in patients, activity, age, but as well BMI, were 
comparable between those trials. Unfortunately, most trials had a high drop 
out rate. Even after 20 years of ACI-trials long-term data are still missing. 
Furthermore, both histological and immunohistochemical methods showed 
the development of mixed cartilage, consisting of both fibrous tissue and 
hyaline tissue, to be the best ACI outcome, but none of those trials had re-
ported the percentage of this ratio or its development. No trial used medium 
density gene expression profiling for analysis. 
Due to inconsistent reporting of adverse events aggregated statements on the 
safety of ACI-techniques are barely possible. Nevertheless microfracture and 
mosaicplasty seem to have both slightly lower rates of adverse events than 
the ACI technique. Hypertrophy of cartilage seem to be an important safety 
issue. The need for quality assurance standards and the relevance for the 
impact on cultivation of the cells is reasonable. Development of MRI and 
molecular biological methods, can lead to a better understanding of cell be-
haviour, in particular migration abilities, cells re-differentiation and cell di-
vision properties, which is hardly asked in those trials, but frequently their 
were observable malfunctions of these parameters.  
In fact there is only one clinical trial [50] using electron microscopy as pa-
rameter. This trial is reporting differences in between the ACI treated and 
the OCT treated cartilage on cells surface. These patterns have to be ana-
lysed as they must be the result of a change in transcriptional, and reasoned 
by that in a translational and modificational change of proteins´ state. The 
detectable change in mRNA expression can be analysed by use of microar-
ray. There is no doubt that these observation can be performed additionally 
to an histology, caused by the fact that an mRNA analysis is needing only 
small amounts of tissue, and standard samples, for comparison, could be 
taken while the collection of cells for cultivation is taking place. Basically, 
controls are done while cultivation. So the development, analogue to the me-
tabolism products of pharmaceutics, of these cells should be shown.  
Economic aspects of ACI have been discussed in most of the systematic re-
views. All but one review conclude that long term results are needed and 
that there is no trial evidence that the higher costs of the ACI technique are 
justified.  
consistent results 
in several comparative 
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equality of ACI 
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study designs: difficult 
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The influence of baseline BMI and physical activity level of patients was 
shown in all of the studies. Regardless of the type of treatment or the age of 
the patient, it was shown that the higher the Tegner score or the lower the 
BMI at baseline, the better are the outcomes. 
There were no differences between the localisations or aetiology of the 
treated defects. All treatments seem to be similar, or differences in outcome 
were not been reported, apart from Bentley et al. 2003, who reported a better 
development of the medial condyle treatment and this result is not under-
lined by their baseline data. 
ACI vs. (M)ACI outcomes also seem to be very similar. There were fewer 
cases of hypertrophy after ACI-C than ACI-P treatment, but the functional 
scoring systems seem to indicate that ACI-P regeneration properties are 
higher than in ACI-C. Technical development is slower, and leads to a 
poorer outcome than expected. There is no evidence that newer generations 
of technologies are associated with significant outcomes improvements. The 
main differences were observed between ACI-P and arthroscopic ACI-C, 
which is far less expensive, and easier to perform. 
In conclusion, it must be said that ACI methods remain experimental tech-
niques.  
5 Conclusion 
There is no evidence that ACI or MACI leads to better outcomes than any of 
the alternative treatments. ACI is not superior; at best equal, at much higher 
cost. The short term non-inferiority in highly selected active patients is 
proven. Long-term data are lacking. ACI methods must be considered as ex-
perimental techniques.  
Furthermore, there is a need for safety trials that focus on cell migration, or 
absence, the development of re-implanted cells, and the genexpression pro-
files, by use of microarray technology. The expression of genes, responsible 
for surface structure, the proliferation pathways, apoptotic pathways and 
proteins regulating extracellular matrix embedding, should be considered as 
important targets of analysis. The impact of changes in genexpression, and 
protein state, which still are the base of every medical intervention, have to 
be handled with care. There is a doubtless difference between implanted 
chondrocytes and natural chondrocytes. This, by the unknown source of cell-
behaviour change, and the absence of long-term data of ACI, cannot be ig-
nored, and have to be seen as a risk.  
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